Clarithromycin as the empiric antibiotic therapy for medication-related osteonecrosis of the jaw in multiple myeloma patients

Yehuda Zadik*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

1 Scopus citations

Abstract

About half of individuals diagnosed with medication-related osteonecrosis of the jaw (MRONJ) are multiple myeloma (MM) patients, and most are treated using antibiotics for long-term courses. The penicillin group is recommended as the empiric drug of choice, and quinolones, metronidazole, clindamycin, doxycycline, and erythromycin as alternatives. This paper suggests the macrolide clarithromycin as the empiric antibiotic therapy of MRONJ in MM patients because of its better pharmacologic properties in comparison to erythromycin, and the beneficial effect of this agent in MM. This empiric antibiotic regimen should be later adjusted according to the response and findings of the microbial cultures.

Original languageEnglish
Pages (from-to)104-105
Number of pages2
JournalOral Oncology
Volume84
DOIs
StatePublished - Sep 2018

Bibliographical note

Publisher Copyright:
© 2018

Keywords

  • Antibiotics
  • Antimicrobial agents
  • Bisphosphonate
  • Macrolides
  • Oral medicine

Fingerprint

Dive into the research topics of 'Clarithromycin as the empiric antibiotic therapy for medication-related osteonecrosis of the jaw in multiple myeloma patients'. Together they form a unique fingerprint.

Cite this